Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC
Status:
Not yet recruiting
Trial end date:
2030-02-20
Target enrollment:
Participant gender:
Summary
This research study is evaluating effectiveness and safety of a combination of immunotherapy
drug, pembrolizumab, with chemotherapy, as a possible treatment before and after surgery for
squamous cell carcinoma of the head and neck (HNSCC). The combination of pembrolizumab and
chemotherapy will be given prior to your surgery, while immunotherapy pembrolizumab will be
continued for approximately 1 year after surgery.
The names of the study drugs involved in this research study are:
- pembrolizumab (a type of immunotherapy)
- docetaxel (a type of chemotherapy)
- cisplatin (a type of chemotherapy)
- carboplatin (a type of chemotherapy)